Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in Mid-Stage Pancreatic Cancer Study

07/21/2021 | 02:44pm EDT


ę MT Newswires 2021
All news about MERCK & CO., INC.
10:59aMERCK : Announces KEYTRUDA« (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) ..
BU
07:57aMERCK : Says Keytruda Met Primary Endpoint of Overall Survival in Patients With Liver Canc..
MT
07:44aMERCK : LYNPARZA (olaparib) in combination with abiraterone significantly delayed disease ..
AQ
07:44aMERCK : LYNPARZA (olaparib) in Combination With Abiraterone Significantly Delayed Disease ..
AQ
05:56aMerck Says Keytruda Liver Cancer Study Meets Objective
DJ
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
09/24AstraZeneca and Merck Announce Positive Results from the Phase 3 PROpel Trial
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,1x
Yield 2021 3,52%
Capitalization 186 B 186 B -
EV / Sales 2021 4,30x
EV / Sales 2022 3,89x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,61 $
Average target price 93,42 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.01%186 334
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037